Table 2.
Relative CNS tissue levels of NAGLU following IV and ICV administration of BMN 250 to healthy non-human primates
| CNS tissue | Dose-normalized % recovery IV/ICV | Absolute % recovery IV/ICV |
|---|---|---|
| Cerebellum—deep | 5.3% | 26.5% |
| Cerebellum—superficial | 4.5% | 22.5% |
| Cerebral (frontal) cortex—deep | 16.2% | 81% |
| Cerebral (frontal) cortex—superficial | 30.5% | 152% |
| Medulla oblongata—deep | 30.5% | 152% |
| Medulla oblongata—superficial | 4.3% | 21.5% |
| Midbrain—deep | 2.2% | 11% |
| Midbrain—superficial | 30.7% | 153% |
| Occipital cortex—deep | 14.2% | 71% |
| Occipital cortex—superficial | 13.4% | 67% |
| Spinal cord—cervical | 0.5% | 2.5% |
| Spinal cord—lumbar | 2.5% | 12.5% |
| Spinal cord—thoracic | 9.1% | 45.5% |
| Striatum—deep | 92.7% | 461% |
| Striatum—superficial | 25.6% | 128% |
| Thalamus—deep | 55.3% | 277% |
| Thalamus—superficial | 62.8% | 314% |
| Mean | 23.6% | 118% |